Panacea Biotec Consolidated March 2021 Net Sales at Rs 168.27 crore, up 34.23% Y-o-Y
NULL03-06-2021
Panacea Biotec Ltd - 531349 - Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended March 31, 2021
In continuation to our letter dated May 24, 2021 and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'), we would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. June 02, 2021 approved the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2021 in terms of Regulation 33 of SEBI LODR Regulations. The same were also reviewed by the Audit Committee in its meeting held earlier on June 02, 2021. A copy of the aforesaid Audited Financial Results (Standalone and Consolidated) along with Auditors' Report is enclosed herewith.02-06-2021
Panacea Biotec Ltd - 531349 - Outcome of Board Meeting (EGM on June 25, 2021)
Panacea Biotec Ltd has informed BSE about Outcome of Board Meeting held on June 02, 2021.02-06-2021
Panacea Biotec Ltd - 531349 - Outcome Of Board Meeting
We would like to inform you that the Board of Directors of the Company has, at its meeting held today 02.06.2021, inter-alia, considered and approved the following:- 1. Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2021. The same were also reviewed by the Audit Committee in its meeting held earlier on 02.06.2021. 2. Raising of funds by the Company through one or more permissible mechanisms as may be deemed appropriate by the Board, for an amount upto and not exceeding INR 12,000 million or its equivalent in any other currency(ies), in one or more tranches, subject to the approval of the Shareholders of the Company and any other regulatory or statutory approvals, as may be required; and 3. Convening of EGM of the Company on 25.06.2021 at 11:30 A.M. through Video Conferencing / Other Audio-Visual Means. The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 07:15 P.M.02-06-2021
Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Raising of Funds
Pursuant to Regulation 29(1)(d) of SEBI LODR Regulations, 2015 and other applicable rules and regulations, we would like to inform that the Board in the said Meeting would also, inter-alia, consider and evaluate any and all proposals for raising of funds by the Company through one or more permissible mechanisms as may be deemed appropriate by the Board, by way of issuance of equity shares and / or other securities including share warrants, bonds, foreign currency convertible bonds, debentures and / or any other equity based instruments / securities including through qualified institutions placement, preferential issue, private placement, rights issue, or through any other permissible mode or any combination thereof in the domestic and / or international markets and / or by way of raising debt funds including ECB, as may be permitted under applicable laws, in one or more tranches, subject to receipt of regulatory / statutory / shareholders approvals, as may be required.27-05-2021
Panacea Biotec share price hits 5% upper circuit on launch of Sputnik V production
The production of Sputnik V was launched on May 24 at the firm's Baddi facility in Himachal Pradesh, the company has said.25-05-2021
Panacea Biotec Ltd - 531349 - Board Meeting Intimation for Approving The Standalone And Consolidated Audited Financial Results For The Quarter / Financial Year Ended March 31, 2021
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2021 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter / Financial Year ended March 31, 2021. Further, pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company. Further, with reference to our earlier announcement dated March 31, 2021 intimating the Closure of Trading Window pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company till June 04, 2021 and the same will re-open from June 05, 202124-05-2021
Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Panacea Biotec Ltd. is delighted to inform that the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, has today announced the launch of production of the Russian Sputnik V vaccine against coronavirus at Panacea Biotec's facilities at Baddi, Himachal Pradesh, India. A copy of the Press Release titled 'RDIF and Panacea Biotec launch the production of Sputnik V in India' being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt24-05-2021
Panacea Infosec announces 30-40% salary hike, to raise headcount by 35%
Cybersecurity firm Panacea Infosec has given 30-40 per cent hike in salaries for all employees with effect from April, the company said on Thursday. Currently, the company has around 230 employees and plans to increase headcount in the range of 25-35 per cent during the ongoing financial year, it said in a statement. "With this hike, Panacea Infosec will get an average increment of 30-40 percent in the financial year 2021-22. "Panacea Infosec is one of the fastest growing cybersecurity audit firms in India with an average growth rate of 245 per cent in the past three years," the statement said. Founded in 2012, the Delhi-based company claims to have over 400 clients spread across 45 countries. Panacea said businesses are still coping up with the COVID-19 crisis, and dependency on information technology and other digital services has increased which, in turn, increased the demand for cybersecurity and privacy services. In the new business environment cybersecurity and audit servic20-05-2021
PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Serum Institute of India Pvt Ltd18-05-2021